Clinical TrialID 1424
Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice
NCT04918264
Digestive Carcinoma
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 1424
- Evidence Id
- 1424
- Core Evidence Id
- 1424
- Source Clinical Trial Id
- 1404
- Herb2 Clinical Trial Id
- HBCT001404
- Nct Id
- NCT04918264
- Title
- Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice
- Status
- Completed
- Phase
- Study Result
- No
- Study Condition
- Digestive Carcinoma
- Study Type
- Observational
- Study Design
- Observational Model: |Time Perspective: p
- Intervention
- DRUG: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|OTHER: Uracil dosage|BEHAVIORAL: Overall survival
- Intervention Allocation
- Intervention Model
- Intervention Mask
- Intervention Purpose
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 334
- Outcome Measure
- Overall survival according to plasma uracil concentration, Last completion date March 30th 2021
- Sponsor Collaborator
- Hospices Civils de Lyon
- Funded By
- OTHER
- Location
- Hopital Edouard Heriot, Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon], Lyon, 69003, France|Hopital de la Croix Rousse, Lyon, 69004, France|Centre Hospitalier de Lyon Sud, Pierre-Bénite, 69495, France
- Other Id
- 69HCL21_0489
- Start Date
- 2020-11-02
- Primary Completion Date
- 2021-02-10
- Completion Date
- 2021-04-15
- First Posted
- 2021-06-08
- Results First Posted
- Last Update Posted
- 2021-06-08
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT04918264
- Title Cn
- Title En
- Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice
- Bilingual Status
- semi_complete